News & Events

Selinexor and Docetaxel Indicate Promise in KRAS-Mutant NSCLC

Selinexor and Docetaxel Indicate Promise in KRAS-Mutant NSCLC

Stage Ⅳb Pulmonary Sarcomatoid Carcinoma with EGFR L861Q KRAS Co-mutation and High PD-L1 Expression Neoadjuvant Immunochemotherapy Combined with Surgery Achieves Near MPR

Stage Ⅳb Pulmonary Sarcomatoid Carcinoma with EGFR L861Q KRAS Co-mutation and High PD-L1 Expression Neoadjuvant Immunochemotherapy Combined with Surgery Achieves Near MPR

Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond

Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond

KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence

KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence

U.S. Clinical Trial: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Listed a New Clinical Trial to Study Glecirasib Combined With Ivonescimab for First-line...

U.S. Clinical Trial: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Listed a New Clinical Trial to Study Glecirasib Combined With Ivonescimab for First-line...

Merck Launches Phase 3 KANDLELIT-007 Trial in KRAS G12C NSCLC

Merck Launches Phase 3 KANDLELIT-007 Trial in KRAS G12C NSCLC